Sonic hedgehog (Shh), both as a mitogen and as a morphogen, plays an important role in cell proliferation and differentiation during early development. Here, we show that Shh inhibits glutamate transporter activities in neurons, rapidly enhances extracellular glutamate levels, and affects the development of epilepsy. Shh is quickly released in response to epileptic, but not physiological, stimuli. Inhibition of neuronal glutamate transporters by Shh depends on heterotrimeric G protein subunit Ga i and enhances extracellular glutamate levels. Inhibiting Shh signaling greatly reduces epileptiform activities in both cell cultures and hippocampal slices. Moreover, pharmacological or genetic inhibition of Shh signaling markedly suppresses epileptic phenotypes in kindling or pilocarpine models. Our results suggest that Shh contributes to the development of epilepsy and suppression of its signaling prevents the development of the disease. Thus, Shh can act as a modulator of neuronal activity, rapidly regulating glutamate levels and promoting epilepsy.
Introduction
The hedgehog family of secreted proteins controls a wide variety of processes in embryonic development, stem cell maintenance, and cancer cell proliferation [1] . Shh is one of the three members in the family and has important roles in early neuronal development, including axon guidance [2] , neuronal differentiation [3] , and cortical microcircuit formation [4] . When Shh is released by the secretion cells, it binds to Patched (Ptch1) to relieve its inhibition on Smoothened (Smo), a transmembrane protein homologous with members of G-protein-coupled receptors (GPCRs), and thus trigger responses, leading to enhanced Gli or Ci (in Drosophila) expression and Gli/Ci-dependent transcription [5] . As most of the effects of Shh are mediated by Gli transcription, its expression levels are always used as an indicator of the activation of this signaling [5, 6] . It has been reported that in mouse embryonic stem cells and developing spinal neurons [3, 7] , Shh can induce an intracellular Ca 2+ elevation. Shh and its signaling molecules are also expressed in mature central nervous system (CNS) though their functions are not clear [8] [9] [10] . Epilepsy is one of the most common chronic neurological disorders with the characteristic of recurrent unprovoked seizures. About one percent of population worldwide has been diagnosed with epilepsy [11] . Individuals who got the first unprovoked seizure have a high risk to expect a recurrence within 2 years of the initial seizure. Understanding of the mechanism underlying epileptogenesis is critical for prevention and treatment of epilepsy. Generally, epileptic seizures result from an imbalance between neuronal excitation and inhibition. As the principal excitatory neurotransmitter in the mammalian brain, glutamate depolarizes neurons, which inevitably plays a role in the initiation and spreading of seizure activity, even when the primary defect is not of glutamatergic origin [11, 12] . Therefore, it is of vital importance that the extracellular glutamate level is kept low [13] . Since there seem to be no extracellular enzymes which can efficiently metabolize glutamate, the only rapid way to clear glutamate from the extracellular fluid is by cellular uptake [14] , a task predominantly operated by the glutamate transporters. It has been known for decades that glutamate uptake activity is not constant, but subject to regulation [14] . Down-regulation of glutamate transporters in mice was found to cause spontaneous seizures [15] [16] [17] .
Five members of excitatory amino acid transporter proteins (EAATs) have been identified and named as EAAT1-5 in mammals [14, 18] . Among them, EAAT1 (GLAST), EAAT2 (GLT-1), and EAAT3 (EAAC1) are expressed in hippocampus and cortex throughout the developing and adult stage [14, 18, 19] . The EAAC1 is localized to neurons, whereas GLAST and GLT-1 predominantly to glia [14, 18, 19] . When a glutamate is taken into the cell by the glutamate transporters, 3Na + and 1H + influx and 1K + efflux are associated to generate a depolarization current [14, 19] . The expression of these transporters can be regulated by growth factors to affect the homeostasis of synaptic glutamate levels, though the regulation of their activities remains controversial [14, 20] . It has been reported that Shh expression in temporal lobe epileptic foci of the patients is greatly increased, indicating that Shh may participate in the changes that occur during temporal lobe epileptic development [21] . Here, we report that Shh can enhance the extracellular glutamate levels and control epileptogenesis.
Results and Discussion

Shh release and its pathway activation under epileptic stimulation
We initially studied the expression pattern of molecules associated with Shh pathway in rat hippocampus, including Ptch1, Smo, and Gli, and found that they were expressed from early stages to adulthood (Fig EV1A and B) and functional in cultures (Fig EV1C and  D) . We then examined the influence of limbic seizures on Shh pathway and found that a 2-h status epilepticus (SE) induced by pilocarpine (Fig 1A-C) or one electrographic seizure induced by kindling stimuli (Fig 1D-F) all increased Gli1 protein levels in the cortex and hippocampus within 24 h (Figs 1A-F and EV1F-I). By contrast, Shh expression was not changed in the same period (Figs 1A-F and EV1E and G). These results suggest that Shh pathway is activated likely due to Shh release in epilepsy rather than enhanced expression level of Shh. To test whether Shh is indeed released under epileptic stimulation, we examined Shh levels in vivo from hippocampi and cortex in pilocarpine model. The levels of Shh detected by enzyme-linked immunosorbent assay (ELISA) were significantly increased 0.5, 1, and 1.5 h after the seizure induction (Fig 1G) . Also, Shh levels in the medium of slices or hippocampal neurons incubated in the medium with picrotoxin (Pic) or Mg 2+ -free (0Mg), conditions known to induce epileptiform activities in slices or cells [22] [23] [24] , were markedly enhanced within 1 h in hippocampal slices (Fig 1H) or 15 min in hippocampal neurons (Fig 1I) . Thus, epileptic neuronal activity rapidly increases Shh release. Consistently, up-regulation of Gli1 in neurons was found 4 h after the incubation in 0Mg for 30 min (Fig 1J) , suggesting that Shh pathway was activated by the secreted Shh.
However, increase of Shh release was not found under physiological conditions, such as theta-burst stimulation (TBS), 20-Hz stimulation, or 50-mM-KCl stimulation (Fig EV2A-C) . Moreover, inhibition of Shh signaling did not change neuronal transmission in physiological conditions, including basal synaptic transmission, AMPA receptor-mediated excitatory postsynaptic current (AMPA-EPSC), paired-pulse facilitation, or long-term potentiation (LTP) (Fig EV2D-G) . These results suggest that Shh did not have any role in the physiological conditions. Therefore, compared with other factors (BDNF, NGF or NT-3, etc.) [11, 25] whose secretion can be increased in response to both LTP and epileptic stimulations, Shh is unique in its release in epilepsy and in regulation of neural activity, but not synaptic efficacy.
Inhibiting Shh pathway reduces the epileptiform activity
We next investigated whether Shh is involved in the formation of epileptiform activities. Neurons incubated in 0Mg medium for 30 min showed the robust epileptiform activity with a train of high-frequency action potentials overlaying on the plateau of large depolarization shifts with the frequency of 7.38 AE 0.56 or 6.52 AE 0.58 burst/min (Fig 2A-C, E left panel or Fig EV2H) . In the presence of cyclopamine or Sant-1, agents known to specifically inhibit Smo [26, 27] , the frequency was 0.22 AE 0.09 or 0.64 AE 0.18 burst/min, respectively (Fig 2A-C and E left panel, and Fig EV2H) . All neurons incubated with 0Mg medium showed epileptiform activities, whereas in the presence of cyclopamine or Sant-1, 26.32% or 54.55% exhibited such activities (Fig 2C and D left  panel) . Moreover, robotnikinin, an agent targeting Shh [28] , and 5E1, a Shh-neutralizing antibody [29, 30] , both reduced the epileptiform activities (middle and right panels of Fig 2D and E; Fig  EV2I and J) . Additionally, in the hippocampal slices the overall frequency of spontaneous epileptiform bursts induced by picrotoxin was reduced from 8.07 AE 0.52 bursts/min to 6.09 AE 0.55 by cyclopamine (Fig 2F-H) . Meanwhile, the expression of Gli1 or Gli2 was not changed when neurons or slices were treated with Shh or the inhibitors in Mg 
Shh increases the extracellular glutamate levels
To explore the mechanism by which Shh regulates epileptic activities, we assessed its effect on Ca 2+ changes in hippocampal neurons. Shh induced a slow and sustained intracellular Ca 2+ elevation in an NMDA receptor (NMDAR)-dependent manner (Fig EV3A-D) , but it did not influence NMDA-or AMPA-induced currents, suggesting that Shh did not directly affect these receptors (Fig EV3E and F) . Under Mg
2+
-free or Pic conditions, whole-cell recording can detect a large and slow NMDA receptor current, the tonic NMDA receptor current, an indication of ambient glutamate in the extracellular space [31] . By application of D-CPP, an antagonist to the NMDA receptors, the amplitude of the tonic NMDA receptor currents can be measured (Fig EV3G and H) . Cyclopamine greatly reduced the tonic NMDA receptor currents in both hippocampal slices and neurons (Fig 2I and J) . However, the NMDA-induced currents were not affected by cyclopamine (Fig EV3I) . Together, these results support an explanation that Shh increases extracellular glutamate to induce the NMDAR currents. Indeed, Shh markedly increased the glutamate levels in the culture medium in a cyclopamine-sensitive manner (Fig 3A) . In contrast, Shh did not affect the neuronal excitability (Fig EV3J-L) . We then explored whether Shh increases glutamate release or inhibits its uptake. In the paired-pulse facilitation experiments, the pairedpulse ratio was not different between vehicle-and Shh-incubated hippocampal slices (Fig 3B) . Therefore, it is unlikely that Shh affects glutamate release. In contrast, Shh greatly inhibited 3 Hglutamate uptake in hippocampal neurons (Fig 3C) . This inhibition was reversed by cyclopamine ( Fig 3C) . Together, these results suggest that Shh inhibits glutamate uptake to increase extracellular glutamate levels. Shh levels assayed by ELISA from mouse cortex and hippocampus at the indicated time after the initiation of status epilepticus (SE) induced by pilocarpine (n = 7-10). H, I Shh levels assayed by ELISA in the medium of slices (H, n = 9) or hippocampal neurons (I, n = 6) incubated with picrotoxin (Pic) or Mg 2+ -free (0Mg) for the indicated times. J Representative Western blots and quantification of Gli1 expression levels from hippocampal neurons incubated with 0Mg for the indicated times (n = 13-19).
Data information: a-Tubulin (a-Tub) was used as a loading control. Data are mean + SEM. *P < 0.05; **P < 0.01; ***P < 0.001 vs. Control (Ctrl) with Student's t-test. We then studied whether Shh regulates glutamate transporter activities. We found that cyclopamine no longer inhibited the epileptiform activity in the presence of TBOA, a non-selective antagonist of glutamate transporters (Fig EV4A-C) , suggesting that cyclopamine and TBOA might act on the similar pathway to regulate the epileptic activities. It has been reported that glial transporters are barely expressed in culture systems [32, 33] . Consistently, the glutamate uptake in neuronal cultures was slightly inhibited by dihydrokainate (DHK), a selective inhibitor of GLT-1 [14] ( Fig EV4D) . In contrast, expressing EAAC1 RNAi, but not GLAST RNAi, inhibited the glutamate uptake (Figs 3D and EV4E-G), suggesting that EAAC1 is the main glutamate transporter in the cultured neurons. Moreover, Shh no longer suppressed the glutamate uptake when the EAAC1 RNAi was expressed ( Fig 3D) . Additionally, aspartate (Asp), a nonselective agonist of glutamate transporters, induced an inward current in neurons, which was blocked by EAAC1 RNAi (Fig 3E) . Inhibiting GLT-1 and GLAST did not change the inward current ( Fig EV4H) . Therefore, EAAC1-dependent current was the major component of Asp-induced current in the cultures. Further, Shh reduced the Asp-induced inward current density in a manner that was sensitive to cyclopamine (Figs 3F and EV4I). In the presence of TBOA, cyclopamine no longer affected Shh inhibition of EAAC1 current ( Fig EV4J) . In addition, Shh also increased extracellular glutamate and reduced the EAAC1 current in the cultures treated H-glutamate uptake caused by expressing EAAC1 (Fig 3G) . Collectively, these results suggest that Shh inhibits EAAC1 activities to elevate the extracellular glutamate.
EMBO reports
It has been reported that Smo can signal through Ga i/o , but not members of G s , G q , and G 12 families, to regulate downstream effectors [35] [36] [37] . Pretreatment of the neurons with pertussis toxin (PTX), an agent known to selectively inhibit Ga i/o [35] , blocked the increase in extracellular glutamate levels, prevented Shh inhibition of glutamate uptake, and reversed the inhibition of EAAC1 current (Figs EV4M and 3H and I), suggesting that Ga i/o protein is necessary for Shh to inhibit EAAC1 activity. To detail Shh regulation of EAAC1 activity, we examined the I-V curve or Asp dose-response curve of EAAC1 (Fig EV4N and O) and found that neither of them was affected by Shh. Further, the expression level of EAAC1 was unchanged 30 min after treatment with Shh ( Fig EV4P) . Using the sucrose gradient centrifugation (0.3-2.0 M gradient) to isolate the subcellular fractions from hippocampal neurons, we found that Smo, Ga i1-3 , Gb, and EAAC1 were mainly presented in the same fractions ( Fig EV4Q) . Together, these results point to a possibility that Shh inhibits EAAC1 activity by suppressing its surface expression to elevate extracellular glutamate in a manner that is dependent on Ga i . Data information: Unless stated, 10 lM cyclopamine was used. Data are mean + SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Ctrl; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. 0Mg or Pic; & P < 0.05 vs. 0Mg + IgG. Statistical analysis: one-way ANOVA (C-E) and Student's t-test (H-J).
▸ Figure 3 . Shh inhibits glutamate transporter activities and increases the extracellular glutamate levels. Inhibiting Shh pathway suppresses epileptogenesis
We next explored the possible role of Shh in epilepsy using the mouse kindling model (Fig EV5A) , which is commonly used to quantify the epilepsy development [11] . Cyclopamine greatly delayed the development of epilepsy, as evidenced by slowed progression of behavioral seizure class and decreased prolongation of electrographic seizure duration (ESD) (Fig 4A and B) . Aldh1l1-Cre mice, in which Smo was specifically ablated in Aldh1l1-positive astrocytes (Fig EV5C) . Down-regulation of Smo in astrocytes also suppressed the epilepsy development (Fig 4J-L) . No difference in the basal electrographic seizure threshold was observed between genetically modified mice and their controls (Fig EV5G and H) . Therefore, Smo in both neurons and astrocytes participates in epilepsy development in mouse kindling models. Since stimulation of Shh pathway increased extracellular glutamate in vivo (Fig EV4R) and glutamate transporter family displays a considerable homology (50-60% at the amino acid level) [39] , it is likely that the activity of transporters, including GLT-1 and GLAST, can be also regulated by Shh to contribute to the enhancement in extracellular glutamate.
It has been reported that elevation of glutamate levels plays a crucial role in spontaneous seizures induced by pilocarpine [40, 41] . To further test the effects of Shh inhibition on epileptogenesis, we examined the frequency of spontaneous seizures in pilocarpineinduced spontaneous seizures. in every week of time (Fig 4M) . Overall, 68.18% of control mice developed class 5 seizure within 8 weeks, whereas 21.74% of cyclopamine-treated mice did (Fig 4N) . Together, these results are consistent with an explanation that Shh pathway contributes to the development of epilepsy. Therefore, Smo could be a novel target for anti-epileptogenesis therapy.
Here, we report a novel function of Shh in CNS. Our data show that Shh is specifically released under epileptic stimulations and regulates the extracellular glutamate levels independent of enhanced Gli expression in the hippocampal neurons. The current findings led us to propose a model that epileptic activity induces Shh release to activate Smo and trigger subsequent responses, including stimulation of Ga i proteins, inhibition of surface expression of the neuronal glutamate transporter EAAC1, increase in extracellular glutamate levels, and enhancement in neuronal activities, contributing to epileptogenesis (Fig 4O) . Therefore, Shh-glutamate signaling likely initiates a positive feedback to amplify the network excitation to promote the development of epilepsy. Our findings thus provide evidence to explain the fact that people face much higher risk of permanent epilepsy after one experience of seizure. Thus, Smo can induce a long-term effect through the Gli-expression pathway and also induce a short-term effect through the Ga i proteins in neurons. Furthermore, because of the close relationship between glutamate transporters and excitotoxicity, our work also suggests a novel candidate for further study of excitotoxicity-related diseases.
In conclusion, our findings point to a previously unknown role of Shh in modulating extracellular glutamate and in contributing to epileptogenesis independent of Gli transcription and to the existence of Shh-regulated Gi protein and EAAC1 activities that is essential for Shh-controlled neuronal activity. The demonstration of Shhdependent epileptiform activity in cultures and slices and epileptogenesis in animal models further expands our understanding of the diverse functions of Shh. Data information: Cyclo: 10 mg/kg. 5E1: 900 ng/mouse. Data are mean AE SEM from at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 vs. Ctrl with Student's t-test. Aldh1l1-Cre mice were used (Smo +/fl as controls). We used adult male C57BL/6 mice in pilocarpine or kindling epilepsy models. The C57BL/6 mice were from SLAK Laboratory Animal Shanghai China. For transgenic mice, both male and female mice were used in epilepsy experiments. For C57BL/6 mice, male mice were used in the experiments. All animal studies followed the animal welfare guidelines of Institute of Neuroscience, CAS.
Materials and Methods
Animals
Reagents and antibodies
Rabbit anti-Gli1 (2534), anti-Shh (2287), Gli1 blocking peptide (1641S), Shh blocking peptides (13937S), and anti-Ga i1 antibodies were from Cell Signaling; rabbit anti-Gli2, anti-EAAC1, anti-GLAST, and anti-Ga i2 antibodies from Abcam; rabbit anti-Ga i3 from Millipore; and mouse anti-b-actin, anti-a-tubulin, and anti-GAPDH antibodies from Sigma-Aldrich. Fura-2 AM, Alexa Fluor 488-conjugated goat anti-rabbit and Texas-Red-conjugated goat anti-mouse secondary antibodies were from Molecular Probes, and HRPconjugated goat anti-rabbit and anti-mouse secondary antibodies from Amersham. All other reagents were purchased from SigmaAldrich.
Animal models for seizures and epilepsy
Pilocarpine model
Pilocarpine hydrochloride (Sigma-Aldrich) dissolved in 0.9% (wt/vol) sterile saline was intraperitoneally (i.p.) administered to adult male mice (C57BL/6) at a dosage of 300 mg/kg (body weight). Scopolamine methyl nitrate (2 mg/kg, i.p.; Sigma-Aldrich) was injected 30 min before pilocarpine to block peripheral side effects. Diazepam (4 mg/kg, i.p.; Sigma-Aldrich) was used to terminate status epilepticus (SE, 2 h) of continuous seizures to standardize the duration of seizure activity.
To detect Gli1 and Shh levels, mice were killed at varying intervals (6, 12, or 24 h after the termination of SE) and their expression levels in cortex and hippocampi were analyzed. Vehicle (saline, 0.9% wt/vol sterile saline)-injected mice served as controls.
To detect the spontaneous seizures, mice were divided into two groups after SE induction, vehicle (HBC, 45% wt/vol HBC (2-hydroxypropyl-b-cyclodextrin, Sigma-Aldrich) in PBS)-or cyclopamine (Cyclo, 10 mg/kg, Selleckchem, Sigma-Aldrich, Abcam)-treated group. A video monitoring system was used for recording the behaviors at the 4 th , 6 th , and 8 th week (7 h/day, 5 days/week) after SE induction. HBC or Cyclo was administrated every other day from the first day after SE induction to the end of the 8 th week.
To examine Shh release in vivo, mice were killed at varying intervals (0.5, 1, or 1.5 h after the initiation of SE) and their cortex and hippocampi were dissected and ground gently by grinding rod with heparin. The samples were centrifuged at 100 g at 4°C and Shh in the supernatant was determined by ELISA. Animals were divided into groups randomly.
Kindling model
Kindling model was established according to the method described previously with a little modification [42] . We implanted a bipolar electrode used for stimulating and recording stereotactically in the left amygdala of adult mice under sodium pentobarbital anesthesia, at the following coordinates (with bregma as the reference): 1.2 mm posterior, 2.8 mm lateral, and 4.6 mm below dura. Four screws were also inserted into the skull through a drilled hole without piercing the dura. One of the screws served as a ground electrode. The electrodes and screws were fixed with a mixture of acrylic and dental cement. After a recovery period of 5-7 days, we determined the electrographic seizure threshold (EST) for each animal by applying a 1-s train of 1-ms biphasic rectangular pulses at 60 Hz beginning at 60 lA. More stimulation, increasing by 20 lA steps, were delivered at 10 min intervals until an electrographic seizure with a duration of no less than 3 s was detected by the electroencephalogram (EEG) recording from the bipolar electrode. Both EEG and behavioral seizures were recorded. We scored the behavioral progression of stimulation-evoked seizures according to Racine's standard classification [43] with a little modification: 0, no behavioral change; 1, eye blinking and/or facial clonus; 2, head nodding; 3, unilateral forelimb clonus; 4, rearing with bilateral forelimb clonus; 5, generalized clonic convulsions with loss of hind limb control; and 6, severe whole body convulsions with continuous jumping behavior. We defined the fully kindled state as the occurrence of three consecutive class 5 or 6 seizures. We stimulated and recorded each mouse once a day.
To detect Gli1 and Shh expression, mice with an electrographic seizure detected were divided into groups randomly and killed at varying intervals (3, 6 , or 12 h after the stimuli) and their protein levels in cortex and hippocampi were analyzed. Mice undergone surgery but without stimulation were used as controls.
To test the effect of inhibition of Shh pathway on kindling development, Cyclo (10 mg/kg) and its vehicle (HBC), or 5E1 (900 ng/mouse, DSHB) and its control IgG were delivered intraperitoneally (i.p.) or intracerebroventricularly (i.c.v.), respectively, 30 min before each stimulation. Animals were divided into groups randomly.
Cell culture and transfection
Primary hippocampal neurons were isolated and cultured as described previously [44] . Briefly, the neurons were obtained by dissociating the hippocampus from SD rat brains of embryonic day 18 and then seeded at a density of 5 × 10 4 /cm 2 onto coverslips (No.
1 Glass, Warner Instruments, Connecticut, USA) which had been coated with 50 lg/ml poly-D-lysine (Sigma-Aldrich). Cells were cultured in Neurobasal supplemented with B-27 and 0.5 mM glutamax for 9-12 days before use. In ARA-C (cytosine b-D-arabinofuranoside, Sigma C1768, 10 lM) experiments, the ARA-C was added 24-48 h after plating. The HEK293 cells cultured in DMEM supplemented with 10% FBS were transfected with control (1 lg pCIG and 3 lg pEGFP), pEGFP-smoothened (1 lg pCIG and 3 lg pEGFP-constitutively active smoothened), pCIG-EAAC1 (1 lg pCIG-EAAC1 and 3 lg pEGFP), or pCIG-EAAC1 plus pEGFP-smoothened (1 lg pCIG-EAAC1 and 3 lg pEGFP-constitutively active form of smoothened) using Lipofectamine 2000 (Invitrogen).
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Whole-cell recordings in cultured neurons
Whole-cell patch-clamp recordings were carried out at room temperature (22-25°C) at DIV (days in vitro) 9-12. Patch electrodes were pulled with a Flaming/Brown micropipette puller (P-97, Sutter Instruments, USA) and fire-polished. The recording electrodes had a resistance of 4-6 MΩ when filled with different internal solutions. The liquid junction potential was auto-adjusted each time by pipette offset. After the formation of whole-cell recording, access resistances were generally < 20 MΩ.
To record NMDA-activated currents, the pipette solution A (in mM: CsCl 140, EGTA 10, Mg 2 ATP 0.3, CaCl 2 0.3, and HEPES 10, pH adjusted to 7.3 with CsOH) and the external solution (ES) A (in mM: NaCl 140, KCl 5, CaCl 2 1, MgCl 2 1, glucose 10, and HEPES 10, pH adjusted to 7.4 with NaOH) were used. The membrane potential was held at +40 mV. To record AMPA-activated currents, the pipette solution B (in mM: potassium gluconate 120, KCl 20, MgCl 2 2, HEPES 10, EGTA 10, and Na 2 ATP 2, pH adjusted to 7.3 with KOH) and ES A were used. The membrane potential was held at À70 mV.
To record epileptiform discharge or tonic NMDA receptormediated currents, the pipette solution B and the ES B (in mM: NaCl 145, KCl 3, CaCl 2 2, MgCl 2 2, glucose 10, and HEPES 10, pH adjusted to 7.4 with NaOH) were used. In recording of epileptiform discharge, Mg 2+ -free ES (0Mg) was prepared from the external solution B, in which MgCl 2 was omitted. ES was used as a control. Cells were incubated in various ES for 30 min before recordings. In 0Mg+Cyclo group, cells were incubated in ES with Cyclo (10 lM in DMSO, used in all in vitro experiments) for 30 min and then transferred to 0Mg plus Cyclo and incubated for another 30 min. Recordings were performed for 10 min. The epileptiform burst is defined as a large depolarization shift with ≥ 10 mV depolarization and ≥ 300 ms in duration and at least five action potentials as described in the previous study [45] . Neurons with at least two epileptiform bursts during 10 min recording were defined as "neurons showing epileptiform activity" [45] .
In recording of D-CPP (50 lM)-sensitive tonic NMDA currents, 0Mg was used as control. The cells were incubated in 0Mg for 30 min before recording. In 0Mg+Cyclo group, the cells were incubated in the presence of Cyclo for 30 min and then transferred to 0Mg plus Cyclo and incubated for another 30 min. The membrane potential was held at À70 mV.
To record aspartate (Asp, 100 lM)-evoked EAAC1 currents, the pipette solution C (in mM: KNO 3 140, MgCl 2 2.5, HEPES 10, EGTA 11, Na 2 ATP 5, and HEPES 10, pH adjusted to 7.3 with KOH) and the ES C (in mM: NaCl 135, KCl 5.4, CaCl 2 1.8, MgCl 2 1.3, glucose 10, HEPES 10, D-CPPene (NMDA receptor antagonist) 0.05, CNQX (AMPA/KA receptor antagonist) 0.02, and bicuculline (GABA A receptor antagonist) 0.02, pH adjusted to 7.4 with NaOH) were used. The membrane potential was held at À80 mV.
To test the effect of Shh on neuronal excitability, a series of depolarizing currents from 0 to 200 in 5 pA step increment was injected [46] and the resting membrane potential, the averaged current threshold to induce the first action potential, and frequencies of firing in response to 70-, 100-, and 150-pA current injections with or without Shh were determined with pipette solution B and the ES B.
Drug solutions were prepared in external solutions and applied to neurons by pressure using the 8-Channel Focal Perfusion System (ALA Scientific Instruments, USA). Neurons were bathed constantly in external solutions between drug applications. Drug solution exchange was accomplished by electronic control.
Recordings in hippocampal slices
Hippocampal slices were prepared from male SD rats (90-140 g). Animals were anesthetized with 1% pentobarbital sodium, and their brains were rapidly removed. Transverse slices were cut 400 lm thick on a vibration microtome (Leica VT1000S, Leica Microsystems, Wetzlar, Germany) in ice-cold dissection buffer (in mM: sucrose 213.26, KCl 2.5, MgSO 4 2, CaCl 2 0.5, NaH 2 PO 4 1.25, NaHCO 3 26, and D-glucose 10). Before use, the slices were equilibrated in artificial cerebrospinal fluid (aCSF, in mM: NaCl 124, KCl 2.5, MgSO 4 1, CaCl 2 2, NaH 2 PO 4 1.25, NaHCO 3 26, and D-glucose 10) saturated with 95% O 2 /5% CO 2 for at least 1 h. Recordings were in a submerge chamber at a flow rate of 1.5-2 ml/min with aCSF.
To record spontaneous epileptiform discharge, the aCSF containing 6.5 mM KCl and 100 lM picrotoxin (Pic) was used and recordings were performed at 30°C with aCSF as a control. Slices were pre-incubated with DMSO or Cyclo for 30 min and then perfused with Pic or Pic plus Cyclo. Borosilicate glass microelectrodes with 1-3 MΩ resistance filled with aCSF were positioned at CA1 stratum pyramidal. Recordings were performed for 30 min after the frequency of discharge was stabilized.
In paired-pulse experiments, microelectrodes were positioned at CA1 stratum radiatum to record field excitatory postsynaptic potential (fEPSP). Paired-pulse stimuli were delivered at 10, 20, 50, 100, 200, and 500-ms intervals every 20 s at 30-40% of maximal response. Paired-pulse ratio was the percentage of the second stimulus-evoked fEPSP amplitude divided by the first stimulus-evoked fEPSP amplitude in a given paired-pulse stimuli in individual slices.
In recording of AMPA-EPSC, picrotoxin (100 lM) was added with a holding at À70 mV and pipette solution B was used. In LTP experiment, theta-burst stimulation (TBS, five trains of stimuli which contain five burst (five stimuli at 100 Hz) at 5 Hz repeated at 0.1 Hz) was given by a tungsten electrode positioned at striatum radiatum of CA1.
To record D-CPP-sensitive tonic NMDA receptor currents, Pic was used as a control. Whole-cell recordings were performed at CA1 pyramidal neurons with a holding at +40 mV. The inner solution (in mM: CsCl 140, EGTA 10, Mg 2 ATP 0.3, CaCl 2 0.3, and HEPES 10) was used. The cells were incubated in Pic for 30 min before recording. In Pic+Cyclo group, the cells were incubated in the presence of Cyclo for 30 min and then transferred to Pic plus Cyclo and incubated for another 30 min.
Data were acquired using MultiClamp700A and 700B and Digidata1322AA and 1440A (Axon Instruments, California, USA), sampled at 10 kHz, and filtered at 2 kHz. Offline analysis was done by Clampfit 9.0 and 10.2 software (Axon Instruments, California, USA). Shengjie Feng et al Shh is a regulator of glutamate and epilepsy EMBO reports was immediately collected and assayed in the plate coated with anti-Shh antibody. In the TTX experiment, cells were treated with 50 mM KCl, CNQX, 10 lM; APV, 100 lM with or without TTX (1 lM) for 30 min. In the electro-stimulation experiments, the cells were stimulated at 20 Hz for 30 min [47, 48] . All cell experiments used ES as a control. For determination of Shh secretion from slices, acute hippocampal slices (400 lm thick) were transferred to 900 ll oxygen-bubbled aCSF (as a control) or Pic (as in electrophysiology) in 3.5-cm dish and incubated for different times (0.5, 1, or 1.5 h). After incubation, slices were rinsed with manual stir bars, and the supernatant was collected and centrifuged at 4°C for 10 min. To detect the Shh levels under physiological condition, TBS (as in electrophysiology) was given by a tungsten electrode positioned at striatum radiatum of CA1. All the supernatant was applied in one anti-Shh-coated well with a two-step incubation. Shh levels were determined by the ELISA kit (R&D MSHH00) and calculated from the standard curve prepared for each plate, using Origin 7.5 software. The standard curves were linear within the range used (0-500 pg/ml Shh). The quantities of Shh in experimental samples were always within the linear range of the standard curve.
Cytosolic Ca 2+ measurement
Changes in [Ca
2+
] i concentration were measured using Fura-2 AM (Invitrogen). Briefly, a total of 1 × 10 5 primary cultured neurons were seeded on coverslips and incubated with 2 lM Fura-2 AM at 37°C for 25 min. Cells were washed three times with normal external solution (in mM: NaCl 120, KCl 16, CaCl 2 2, MgCl 2 2, glucose 12, sucrose 12, and HEPES-free acid 10, pH 7.4) and imaged using a Nikon Eclipse Ti microscope (Nikon, Japan) with dual excitation wavelengths for Fura-2 AM at 340 and 380 nm and detection of fluorescent emission at 500 nm.
High performance liquid chromatography (HPLC) assay
After two washes with external solution (in mM: NaCl 145, KCl 3, CaCl 2 2, MgCl 2 2, glucose 10, and HEPES 10, pH adjusted to 7.4 with NaOH), cells were incubated with vehicle (bovine serum albumin in external solution, BSA) for 30 min. Then, the incubating solution was collected for HPLC assay as a baseline control. Immediately after removing the solution, cells were treated with either BSA or Shh (Sigma-Aldrich, Selleckchem, 500 ng/ml used in all experiments) for another 30 min. The incubating solution was also collected for HPLC test. The HPLC system (Agilent Jordax Eclipse Plus C18 2.1 mm I.D × 150 mm analytical column, 3.5/micron) and fluorescence detector (Agilent G1321A HPLC-FLD) with excitation wavelength at 340 nm and emission wavelength at 450 nm were used. Column temperature was maintained at 36°C. The mobile phase was formed by methanol, acetonitrile, and water. PerkinElmer) diluted in the uptake buffer. Incubation was at 37°C for 6 min. The reaction was stopped by rapidly adding 1 ml of cold uptake buffer and followed by two washes with the cold medium. Then, 1 N NaOH was added to cells and the radioactivity was assessed by liquid scintillation counting.
Microdialysis
The mice were implanted with CMA 7 guide cannula (CMA microdialysis AB, Kista, Sweden) with the following coordinates (to bregma): 2.5 mm posterior, 3.1 mm lateral, and 2.4 mm below dura. Seven days after implantation, the guide cannula were replaced with CAM 7 microdialysis probes (CMA microdialysis AB, Kista, Sweden), the tip of which was covered with a 1.0 mm length of permeable hollow fiber. The dialysis cannula was connected to a microinfusion pump (CMA/100 microdialysis pump, CAM Microdialysis) and continuously perfused with aCSF at 1.0 ll/min. Following a 2-h stabilization period (the concentration of glutamate is between 2 and 5 lM), the dialysates were collected in tubes at 15-min intervals. The baseline lasted for 60 min before administration of SAG (Smoothened agonist, 4 mM via the microdialysis probe). The HPLC system was used for analysis of glutamate.
RNAi constructs and lentiviral vectors
Specific sequences of short hairpin RNA (shRNA) targeting rat EAAC1, GLAST mRNA sequence and a nonsense shRNA were designed and constructed into the pLentiLox3.7 (pLL3.7) lentiviral vector, which has a GFP tag [49] . Expanded View for this article is available online.
